NeuroPace (NPCE)
(Delayed Data from NSDQ)
$8.70 USD
-0.23 (-2.58%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $8.68 -0.02 (-0.23%) 5:02 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NPCE 8.70 -0.23(-2.58%)
Will NPCE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NPCE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NPCE
Orthofix (OFIX) Q2 Earnings and Revenues Beat Estimates
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
NPCE: What are Zacks experts saying now?
Zacks Private Portfolio Services
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
Other News for NPCE
NeuroPace (NPCE) Welcomes CMS Decision on RNS System Assignment
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with ...
NeuroPace 'commends' CMS for maintaining FY25 epilepsy reimbursement structure
NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025 | NPCE Stock News
Citizens JMP pharmaceuticals analysts hold analyst/industry conference call